Download PDF
Thromb Haemost 2001; 85(05): 945-946
DOI: 10.1055/s-0037-1615779
Letters to the Editor
Schattauer GmbH

Avoiding Overanticoagulation: Pharmacogenomics or Pragmatism?

Trevor Baglin
1   Department of Haematology, Addenbrooke‘s Hospital, Cambridge University Hospitals Trust, Cambridge, UK
› Author Affiliations
Further Information

Publication History

Received 13 December 2001

Accepted 25 January 2000

Publication Date:
11 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Margaglione M, Colaizzo D, D’Andrea G, Brancaccio V, Ciampa A, Grandone E, Di Minno G. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84: 775-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Mannucci P. Genetic control of anticoagulation. Lancet 1999; 353: 688-9.
    CrossrefPubMedGoogle Scholar
  • 3 Aithal G, Day C, Kesteven P, Daly A. Association of polymorphisms in the cytochrtome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9.
    CrossrefPubMedGoogle Scholar
  • 4 Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96: 1816-9.
    PubMedGoogle Scholar
  • 5 Panneerselvam S, Baglin C, Lefort W, Baglin T. Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarin. Br J Haematol 1998; 103: 422-4.
    CrossrefPubMedGoogle Scholar
  • 6 Peters J, Luddington R, Brown K, Baglin C, Baglin T. Should patients starting anticoagulant therapy be screened for missense mutations at ALA-10 in the factor IX propeptide?. Br J Haematol 1997; 99: 467-8.
    PubMedGoogle Scholar